Teva Pharmaceutical Industries Ltd. Slashes Full-Year Outlook After Disappointing Second Quarter
Buying the Actavis Generics business from Allergan (NYSE: AGN) made the difference for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) when it reported first-quarter results in May. That deal boosted Teva's revenue and earnings.
Teva announced its second-quarter results before the market opened on Thursday. This time around, however, the carryover effect from the Actavis Generics acquisition wasn't enough to give investors what they wanted. Here are the highlights from Teva's quarterly update.
Image source: Getty Images.
Source: Fool.com
